You are here

Home » Duke University

Duke University

433A MSRB I103 Research Drive (Box 3156)
Durham, NC 27710
United States

Validating a Mouse Model of Alveolar Rhabdomyosarcoma

Rhabdomyosarcoma

Background

Synergistic Differentiation Therapy in Neuroblastoma

Neuroblastoma

Background

Role of Exon 0 in the Function of Mxi0

Neuroblastoma

Genetic Susceptibility to Pediatric Osteosarcoma and Interaction with Measures of Childhood Growth

Osteosarcoma

This project originated at the University of California San Francisco. Effective July 2017, Dr. Walsh has accepted a new position and will be completing work on his 'A' Award at Duke University in Durham, NC.

The Role of MST1 in Non-canonical Hippo Signaling in Rhabdomyosarcoma

Rhabdomyosarcoma

Background

While overall pediatric cancer patient survival rates have significantly improved over the past 40 years, poor prognosis persists in the aggressive pediatric cancer, alveolar rhabdomyosarcoma (aRMS). aRMS survival rates for high risk groups have not significantly improved in decades, due to an incomplete understanding of the underlying disease mechanisms. Many aRMS tumors harbor an aRMS-specific gene mutation, known as PAX3-FOXO1. However, using experimental approaches, this mutation alone is not sufficient for tumor formation.

Potential of Targeting Glucose Metabolism as a Novel Therapeutic Approach for B cell Acute Lymphoblastic Leukemia (B-ALL)

Leukemia

The Role of the Receptor Tyrosine Kinase FGFR4 in Human Alveolar Rhabdomyosarcoma Tumorigenesis.

Rhabdomyosarcoma

Therapeutic Potential of the MST1/Hippo Tumor Suppressor Pathway in Alveolar Rhabdomyosarcoma

Rhabdomyosarcoma

Background


Alveolar rhabdomyosarcoma (aRMS) is an aggressive cancer of skeletal muscle. Survival for children in high-risk groups is less than 30%, and this has not improved appreciably in over 30 years. aRMS is characterized by the DNA mutation PAX3-FOXO1, which acts in part by tricking cells into thinking they are building muscle. Although PAX3-FOXO1 is found only in aRMS and should be an ideal drug target, it is not druggable.

Clinical Development of RNA Nanoparticle Vaccines Targeting Recurrent Pediatric Brain Cancers

Brain Tumors, Medulloblastoma, Primitive Neuroectodermal Tumor (PNET)

Background

Cancer vaccines are designed to stimulate the immune system into specifically targeting and killing invasive tumor cells. If tumor-specific antigens can be identified, these targets may meet the clear and urgent need for the development of safe and effective vaccines for children with recurrent brain tumors. We hypothesize that nanoparticles loaded with tumor RNA can serve as an effective immunization platform for eliciting potent tumor-specific immune responses in children with recurrent brain cancers.

The Role of Mxi1 in the Modulation N-Myc Function in Neuroblastoma

Neuroblastoma

Neuroblastoma is the third most common childhood cancer. Unfortunately, despite intensive treatment, two-thirds of children with advanced neuroblastoma succumb to their disease. Current intensive therapies have significant side effects, so new treatment options must be developed to improve outcomes in this devastating disease. To do so requires a better understanding of how neuroblastoma cells survive in the face of these intensive therapies.

Pages

Featured Hero

Ellie Jade Timmer

Ellie was a sweet and sassy little girl who brought joy to everyone around her. Shortly after Ellie turned 2 years old, she was diagnosed with a rare leukemia called JMML. Sadly, Ellie passed away, but never lost her smile throughout her fight.
Read more »